Inhibiting Integrin α5 Cytoplasmic Domain Signaling Reduces Atherosclerosis and Promotes Arteriogenesis
Name
e007501.full.pdf
Size
3.9 MB
Format
Adobe PDF
Checksum (MD5)
e6bfb38c2ac19af81acb2506ba402066
Author(s)
Budatha, Madhusudhan
Zhang, Jiasheng
Zhuang, Zhen W.
Yun, Sanguk
Dahlman, James E.
Schwartz, Martin A.
Anderson, Daniel Griffith
Date Issued
January 2018
Journal
Journal of the American Heart Association
Publisher
American Heart Association
Citation
Budatha, Madhusudhan et al. “Inhibiting Integrin Α5 Cytoplasmic Domain Signaling Reduces Atherosclerosis and Promotes Arteriogenesis.” Journal of the American Heart Association 7, 3 (January 2018): e007501 © 2018 The Authors
Version
Final published version
Abstract
Background--Fibronectin in endothelial basement membranes promotes endothelial inflammatory activation and atherosclerosis but also promotes plaque stability and vascular remodeling. The fibronectin receptor α5 subunit is proinflammatory through binding to and activating phosphodiesterase 4D5, which inhibits anti-inflammatory cyclic adenosine monophosphate and protein kinase A. Replacing the α5 cytoplasmic domain with that of a2 resulted in smaller atherosclerotic plaques. Here, we further assessed plaque phenotype and compensatory vascular remodeling in this model. Methods and Results--α5/2 mice in the hyperlipidemic apolipoprotein E null background had smaller plaques in the aortic root, with reduced endothelial NF-κB activation and inflammatory gene expression, reduced leukocyte content, and much lower metalloproteinase expression. However, smooth muscle cell content, fibrous cap thickness, and fibrillar collagen were unchanged, indicating no shift toward vulnerability. In vivo knockdown of phosphodiesterase 4D5 also decreased endothelial inflammatory activation and atherosclerotic plaque size. α5/2 mice showed improved recovery from hindlimb ischemia after femoral artery ligation. Conclusions--Blocking the fibronectin-Integrin α5 pathway reduces atherosclerotic plaque size, maintains plaque stability, and improves compensatory remodeling. This pathway is therefore a potential therapeutic target for treatment of atherosclerosis. Keywords: arteriogenesis; atherosclerosis; fibronectin; inflammation; matrix metalloprotease; phosphodiesterase 4D5; plaque vulnerability
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1161/JAHA.117.007501
